Arrogene

Arrogene, Inc. was founded in 2006 to commercialize novel targeted cancer therapies and proprietary molecular delivery platforms. The founders of Arrogene are primarily involved in the research and development of Polycefin, a breakthrough biopolymer-based nano-delivery platform capable of targeted delivery of proteins, peptides, small molecules, or oligonucleotide treatments.